New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
16:24 EDTFATEFate Therapeutics announces FDA clearance of IND for PROHEMA
Fate Therapeutics announced that the FDA has cleared its Investigational New Drug Application, or IND, for the clinical development of PROHEMA in pediatric patients undergoing hematopoietic stem cell transplantation for the treatment of inherited metabolic disorders, or IMDs. The FDA's clearance of the IND allows the company to begin expanding its clinical investigation of PROHEMA into rare, non-malignant disorders. The company plans to initiate enrollment of the PROVIDE trial in pediatric patients with IMDs in Q4.
News For FATE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 11, 2014
16:10 EDTFATEFate Therapeutics expects phase 2 PUMA study in Q4
The company said, "Our phase 2 PUMA study of PROHEMA is approaching the second planned data safety review by the independent data monitoring committee. We expect this review to occur during Q4...and we expect to open our PROVIDE study in Q4."
16:08 EDTFATEFate Therapeutics reports Q3 EPS (32c), consensus (33c)
Cash and cash equivalents as of September 30 were $45.5M, compared to $54.0M as of December 31, 2013. Fate expects that its existing cash, cash equivalents and marketable securities will be sufficient to fund its operations into early 2016.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use